ABC | Volume 110, Nº2, Fevereiro 2018

Artigo Original Leiria et al Anticoagulantes ininterruptos e ablação de flutter Arq Bras Cardiol. 2018; 110(2):151-156 Fontes de financiamento Opresente estudo não teve fontes de financiamento externas. Vinculação acadêmica Não há vinculação deste estudo a programas de pós-graduação. Aprovação Ética e consentimento informado Este estudo foi aprovado pelo Comitê de Ética do Instituto de Cardiologia / FundaçãoUniversitária deCardiologia sob o número de protocolo UP 5252/16. Todos os procedimentos envolvidos nesse estudo estão de acordo com a Declaração de Helsinki de 1975, atualizada em2013.Oconsentimento informado foi obtido de todos os participantes incluídos no estudo. 1. Doherty JU, Gluckman TJ, Hucker WJ, Januzzi JL, Ortel TL, Saxonhouse SJ, et al. 2017 ACC Expert Consensus Decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017;69(7):871-98. doi: 10.1016/j.jacc.2016.11.024. 2. Kakkos SK, Kirkilesis GI, Tsolakis I. Editor’s choice: efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg. 2014;48(5):565-75. doi: 10.1016/j.ejvs.2014.05.001. 3. Page RL, Joglar J, Caldwell M, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS Guideline for the management of adult patients with supraventriculartachycardia:areportoftheAmericanCollegeofCardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2015;67(13):e27-e115. doi: 10.1016/j.jacc.2015.08.856. 4. Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A, et al. Meta- analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol. 2009;104(5):671-7. doi: 10.1016/j.amjcard.2009.04.040. 5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. 6. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, et al; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. doi: 10.1093/ eurheartj/ehu367. 7. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, et al; ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995-2003. doi: 10.1016/S0140-6736(16)31474-X. 8. Finlay M, Sawhney V, Schilling R, Thomas G, Duncan E, Hunter R, et al. Uninterrupted warfarin for periprocedural anticoagulation in catheter ablation of typical atrial flutter: A safe and cost-effective strategy. J Cardiovasc Electrophysiol. 2010;21(2):150-4. doi: 10.1111/j.1540-8167.2009.01603.x. 9. Wu S, Yang YM, Zhu J, Wan HB, Wang J, Zhang H, et al. Meta-analysis of efficacy and safety of neworal anticoagulants comparedwith uninterrupted vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol. 2016;117(6):926-34. doi: 10.1016/j. amjcard.2015.12.027. 10. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263-72. doi: 10.1378/chest.09-1584. 11. Grönefeld GC, Wegener F, Israel CW, Teupe C, Hohnloser SH. Thromboembolicriskofpatientsreferredforradiofrequencycatheterablation of typical atrial flutter without prior appropriate anticoagulation therapy. Pacing Clin Electrophysiol. 2003;26(1 Pt 2):323-7. PMID: 12687838. 12. Kaiser DW, Streur MM, Nagarakanti R, Whalen SP, Ellis CR. Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. J Interv Card Electrophysiol. 2013;37(3):241-7. doi: 10.1007/ s10840-013-9793-7. 13. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V, et al. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol. 2015;115(1):47-51. doi: 10.1016/j. amjcard.2014.10.005. 14. Kiehl EL, Makki T, Kumar R, Gumber D, KwonDH, Rickard JW, et al. Incidence andpredictorsofrightventricularpacing-inducedcardiomyopathyinpatientswith complete atrioventricular block and preserved left ventricular systolic function. HeartRhythm.2016;13(12):2272-8.doi:10.1016/j.hrthm.2016.09.027. 15. Amara W, Fromentin S, Dompnier A, Nguyen C, Allouche E, Taieb J, et al. Neworal anticoagulants in patients undergoing atrial flutter radiofrequency catheter ablation: an observational study. Future Cardiol. 2014;10(6):699- 705. doi: 10.2217/fca.14.70. 16. Glover BM, Chen J, Hong KL, Boveda S, Baranchuk A, Haugaa KH, et al. Catheter ablation for atrial flutter: a survey by the European Heart Rhythm Association andCanadianHeart RhythmSociety. Europace. 2017;19(4):e1. doi: 10.1093/europace/euw392. 17. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, et al; GARFIELD-AF Investigators. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307- 314. doi: 10.1136/heartjnl-2016-309832. 18. Klimek-PiotrowskaW, HoldaMK, Koziej M, Holda J, Piatek K, Tyrak K, et al. Clinical anatomy of the cavotricuspid isthmus and terminal crest. PLoSOne. 2016;11(9):e0163383. doi: 10.1371/journal.pone.0163383. 19. AsirvathamSJ.Correlativeanatomyandelectrophysiologyfortheinterventional electrophysiologist: right atrial flutter. J Cardiovasc Electrophysiol. 2009;20(1):113-22. doi: 10.1111/j.1540-8167.2008.01344.x. 20. Melo SL, Scanavacca MI, Darrieux FC, Hachul DT, Sosa EA. Ablation of typical atrial flutter : a prospective randomized study of cooled-tip versus 8-mm-tip catheters. Arq Bras Cardiol. 2007;88(3):273-8. doi: http://dx.doi. org/10.1590/S0066-782X2007000300004. 21. Leiria TL, Becker G, Kus T, Essebag V, Hadjis T, Sturmer ML. Improved flutter ablation outcomes using a 10mm-tip ablation catheter. Indian Pacing Electrophysiol J. 2010;10(11):496-502. PMID: 21197277. 22. Feld G, Wharton M, Plumb V, Daoud E, Friehling T, Epstein L; EPT-1000 XP Cardiac Ablation System Investigators. Radiofrequency catheter ablation of type 1 atrial flutter using large-tip 8- or 10-mm electrode catheters and a high-output radiofrequency energy generator: results of amulticenter safety and efficacy study. J AmColl Cardiol. 2004;43(8):1466-72. doi: 10.1016/j. jacc.2003.11.036. 23. Leiria TL, Pellanda L, MiglioranzaMH, Sant’anna RT, Becker LS, Magalhães E, et al. Warfarin and phenprocoumon : experience of an outpatient anticoagulation clinics. Arq Bras Cardiol. 2010;94(1):41-5. http://dx.doi . org/10.1590/S0066-782X2010000100008. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 156